Ovarian Cancer

Although performance category weightings remain unchanged from 2019, the Centers for Medicare & Medicaid Services has raised the bar for participating providers by increasing the performance threshold from 30 to 45 points in 2020.
The use of combination therapies in the first- and second-line settings for advanced ovarian cancer has the potential to improve patient outcomes.
Although federal reform efforts are likely to stall in the Senate, legislation prohibiting gag clauses, claw backs, and price spreading are being passed at the state level.
Patients and healthcare providers should be aware of the toxicities that may occur with the use of PARP inhibitors so that they can manage them appropriately.
Results from 3 clinical trials demonstrate the value of PARP inhibitors as first-line or maintenance therapies in patients with advanced ovarian cancer.
The Final Rule by the HSS means that manufacturers’ copay cards or coupons do not apply to a patient’s deductible or out-of-pocket maximum limits in certain situations, but further clarification is needed.
CMS approves changes allowing limited utilization management in protected classes of drugs. However, other proposed changes that would have further eroded patient access were not implemented.
A bipartisan bill designed to remove disparity in pricing between intravenously administered drugs and orally administered drugs for patients with cancer was passed in the House in March 2019 but awaits action in the Senate.
There are important changes to beneficiaries’ Medicare Part D prescription drug coverage for 2020. These changes will affect many patients’ out-of-pocket spending for anticancer drugs, including poly (ADP-ribose) polymerase inhibitors.
The ovarian cancer patients’ internal dialogue may delay a cancer diagnosis and can also overestimate the capability of chemotherapy.
Page 1 of 3
Results 1 - 10 of 21